NuoHui Venture Fund
诺辉创投基金
NuoHui Venture Fund (诺辉创投) is a venture capital fund that appears in elsewhere's corpus primarily as a co-investor in biotech and healthcare deals. It participated in Mirxes's $87 million Series C round in 2021 alongside lead investor China Resources Zhengda Life Science Fund, Rock Springs Capital, EDBI and others , and reappeared in the Singapore-based miRNA cancer-screening company's $50 million Series D in 2023 . The fund's name also surfaces in the 2021 Gaorong Ventures monthly report as part of that same Mirxes financing . Elsewhere's corpus does not contain additional detail on the fund's founding, team, or overall strategy beyond these co-investment mentions.
AI-generated — may contain errors, please verify.
Coverage
Mirxes Completes $50 Million Series D to Accelerate Cancer Early-Screening Pipeline R&D and Commercialization
Focused on innovative blood-based early screening products and services for cancer.
Gaorong Monthly · October | Gaorong Ventures Named Among Zero2IPO's Top 10 VC Firms of the Year; Nuro Closes Major Series D Round
Autonomous driving, healthcare, and chip sectors see new funding rounds; Genki Forest unveils "Triple Zero Factory" strategy; Dingdong Maicai stabilizes prices and ensures supply.
Mirxes Completes $87 Million Series C Round to Develop Early Cancer Screening Products Based on Leading miRNA Technology
Focused on microRNA technology, dedicated to early disease diagnosis.
